Switch theme
Sign up to access all valuation multiples
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
1994
82.9K+
LTM Revenue $49.0B
LTM EBITDA $14.3B
$156B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Sanofi has a last 12-month revenue of $49.0B and a last 12-month EBITDA of $14.3B.
In the most recent fiscal year, Sanofi achieved revenue of $48.4B and an EBITDA of $12.0B.
Sanofi expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Sanofi valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $50.7B | $48.4B | XXX | XXX | XXX |
| Gross Profit | $34.6B | $35.2B | XXX | XXX | XXX |
| Gross Margin | 68% | 73% | XXX | XXX | XXX |
| EBITDA | $13.8B | $12.0B | XXX | XXX | XXX |
| EBITDA Margin | 27% | 25% | XXX | XXX | XXX |
| Net Profit | $9.1B | $5.9B | XXX | XXX | XXX |
| Net Margin | 18% | 12% | XXX | XXX | XXX |
| Net Debt | $6.9B | $8.4B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of March 14, 2025, Sanofi's stock price is EUR 106 (or $116).
Sanofi has current market cap of EUR 133B (or $145B), and EV of EUR 143B (or $156B).
See Sanofi trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $156B | $145B | XXX | XXX | XXX | XXX | $8.05 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of March 14, 2025, Sanofi has market cap of $145B and EV of $156B.
Sanofi's trades at 3.2x LTM EV/Revenue multiple, and 11.0x LTM EBITDA.
Analysts estimate Sanofi's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Sanofi and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $156B | XXX | XXX | XXX |
| EV/Revenue | 3.2x | XXX | XXX | XXX |
| EV/EBITDA | 13.0x | XXX | XXX | XXX |
| P/E | 23.9x | XXX | XXX | XXX |
| P/E/Growth | 0.6x | XXX | XXX | XXX |
| EV/FCF | 24.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpSanofi's NTM/LTM revenue growth is 7%
Sanofi's revenue per employee for the last fiscal year averaged $0.6M, while opex per employee averaged $0.3M for the same period.
Over next 12 months, Sanofi's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Sanofi's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Sanofi and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -5% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -12% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 31% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.6M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.3M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 17% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 49% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sanofi acquired XXX companies to date.
Last acquisition by Sanofi was XXXXXXXX, XXXXX XXXXX XXXXXX . Sanofi acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Sanofi founded? | Sanofi was founded in 1994. |
| Where is Sanofi headquartered? | Sanofi is headquartered in France. |
| How many employees does Sanofi have? | As of today, Sanofi has 82.9K+ employees. |
| Who is the CEO of Sanofi? | Sanofi's CEO is Mr. Paul Hudson. |
| Is Sanofi publicy listed? | Yes, Sanofi is a public company listed on PAR. |
| What is the stock symbol of Sanofi? | Sanofi trades under SAN ticker. |
| When did Sanofi go public? | Sanofi went public in 1999. |
| Who are competitors of Sanofi? | Similar companies to Sanofi include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Sanofi? | Sanofi's current market cap is $145B |
| What is the current revenue of Sanofi? | Sanofi's last 12-month revenue is $49.0B. |
| What is the current EBITDA of Sanofi? | Sanofi's last 12-month EBITDA is $14.3B. |
| What is the current EV/Revenue multiple of Sanofi? | Current revenue multiple of Sanofi is 3.2x. |
| What is the current EV/EBITDA multiple of Sanofi? | Current EBITDA multiple of Sanofi is 11.0x. |
| What is the current revenue growth of Sanofi? | Sanofi revenue growth between 2023 and 2024 was -5%. |
| Is Sanofi profitable? | Yes, Sanofi is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
